Klinische Studien zu Hauttumoren

Hier finden Sie eine Aufstellung der derzeit laufenden, offenen klinischen Studien zu Hauttumoren. Bitte zögern Sie nicht die entsprechenden Studienleiter bei Fragen zu kontaktieren.

Melanom – 1st und 2nd line

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02D

Melanom – 1st line

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02B
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02C

Melanom – 2nd line

Melanom – Adjuvant

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma

Lymphom / Nichtmelanozytärer Hautkrebs (NMSC)

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.